A phase III, open-label, randomized, controlled study to evaluate the immunogenicity and safety of inactivated poliovirus vaccine (IPV) when co-administered with Porcine circovirus (PCV)-free liquid formulation of an oral live attenuated human rotavirus (HRV) vaccine in healthy Chinese infants
Latest Information Update: 29 Oct 2024
At a glance
- Drugs Poliovirus vaccine inactivated (Primary) ; RIX 4414 (Primary)
- Indications Gastroenteritis; Rotavirus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline Biologicals; GSK
Most Recent Events
- 26 Oct 2024 Status changed from recruiting to completed.
- 23 Apr 2024 Planned End Date changed from 17 Mar 2025 to 19 Nov 2024.
- 23 Apr 2024 Planned primary completion date changed from 16 Dec 2024 to 19 Nov 2024.